Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

5368
CMA
9278
established clinical significance.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. McMillan R, Tani P, Millard F, et al: Platelet-associated and plasma
anti-glycoprotein autoantibodies in chronic ITP. Blood 1987;70:1040-1045 2. Moore SB, Wick MR,
Richardson LM: Immune thrombocytopenias: tests for platelet antibodies. Mayo Clin Proc
1984;59:860-863 3. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C: Monoclonal
antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of
platelet-reactive antibodies. Blood 1987;70:1722-1726 3. Moore SB, DeGoey SR: Serum platelet
antibody testing: evaluation of solid-phase enzyme immunoassay and comparison with indirect
immunofluorescence. Am J Clin Pathol 1998;109:190-195
Central Nervous System Consultation, Autopsy
Reference Values:
This request will be processed as a consultation. Appropriate dissection will be performed and an
interpretive report provided.
Centromere Antibodies, IgG, Serum
Clinical Information: Centromere antibodies occur primarily in patients with the calcinosis,
Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasis (CREST) syndrome
variant of systemic sclerosis (scleroderma). CREST syndrome is characterized by the following clinical
features: calcinosis, Raynaud's phenomenon, esophageal hypomotility, sclerodactyly, and
telangiectasia.(1) Centromere antibodies were originally detected by their distinctive pattern of
fine-speckled nuclear staining on cell substrates used in the fluorescent antinuclear antibody test.(2) In
subsequent studies, centromere antibodies were found to react with several centromere proteins of 18
kDa, 80 kDa, and 140 kDa named as CENP-A, CENP-B, and CENP-C, respectively.(3) Several putative
epitopes associated with these autoantigens have been described. The CENP-B antigen is believed to be
the primary autoantigen and is recognized by all sera that contain centromere antibodies.
Useful For: Evaluating patients with clinical signs and symptoms compatible with systemic sclerosis
including skin involvement, Raynaudâ€s phenomenon, and arthralgias As an aid in the diagnosis of
calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasis (CREST)
syndrome
Interpretation: In various reported clinical studies, centromere antibodies occur in 50% to 96% of
patients with calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and
telangiectasis (CREST) syndrome. A positive test for centromere antibodies is strongly associated with
CREST syndrome. The presence of detectable levels of centromere antibodies may antedate the
appearance of diagnostic clinical features of CREST syndrome by several years.
Reference Values:
or =1.0 U (positive)
Reference values apply to all ages.
Clinical References: 1. White B: Systemic sclerosis. In Clinical Immunology Principles and
Practice. 2nd edition. Edited by R Rich, T Fleisher, W Shearer, et al. St. Louis, Mosby-Year Book,
2001, Chapter 64, pp 64.1-64.10 2. Tan EM, Rodnan GP, Garcia I, et al: Diversity of antinuclear
antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST
syndrome. Arthritis Rheum 1980;23:617-625 3. Kallenberg CG: Anti-centromere antibodies (ACA).
Clin Rheum 1990;9:136-139
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 423